ACS Infectious Diseases

pubs.acs.org/journal/aidcbc

Article

Non-anticoagulant Heparin as a Pre-exposure Prophylaxis Prevents Lyme Disease Infection

Yi-Pin Lin,* Yanlei Yu, Ashley L. Marcinkiewicz, Patricia Lederman, Thomas M. Hart, Fuming Zhang, and Robert J. Linhardt*

Cite This: ACS Infect. Dis. 2020, 6, 503−514

Read Online

ACCESS | Metrics & More | Article Recommendations | Supporting Information

Downloaded via RENSSELAER POLYTECHNIC INST on March 13, 2020 at 18:35:15 (UTC).
See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.



ABSTRACT: Lyme disease (LD) is caused by the spirochete *Borrelia burgdorferi* sensu lato (*Bbsl*). After transmission to humans by ticks, *Bbsl* spreads to multiple organs, leading to arthritis, carditis, and neuroborreliosis. No effective prophylaxis against human LD prior to tick exposure is currently available. Thus, a pre-exposure prophylaxis (PrEP) against LD is needed. The establishment of LD bacteria at diverse sites is dictated partly by the binding of *Bbsl* to proteoglycans (PGs) and glycosaminoglycans (GAGs) in tissues. The drug heparin is structurally similar to these GAGs and inhibits *Bbsl* attachment to PGs, GAGs, cells, and tissues, suggesting its potential to prevent LD. However, the anticoagulant activity of heparin often results in hemorrhage, hampering the development of this compound as LD PrEP. We have previously synthesized a non-anticoagulant version of heparin (NACH), which was verified for safety in mice and humans. Here, we showed that NACH blocks *Bbsl* attachment to PGs, GAGs, and mammalian cells. We also found that treating mice with NACH prior to the exposure of ticks carrying *Bbsl* followed by continuous administration of this compound prevents tissue colonization by *Bbsl*. Furthermore, NACH-treated mice develop greater levels of IgG and IgM against *Bbsl* at early stages of infection, suggesting that the upregulation of antibody immune responses may be one of the mechanisms for NACH-mediated LD prevention. This is one of the first studies examining the ability of a heparin-based compound to prevent LD prior to tick exposure. The information presented might also be extended to prevent other infectious diseases agents.

KEYWORDS: *Lyme disease, Borrelia, heparin, NACH, pre-exposure prophylaxis*

Transmitted by *Ixodes* ticks, Lyme disease is the most common vector-borne disease in the northern hemisphere.[1,2] This disease is caused by multiple species of the spirochete *Borrelia burgdorferi* sensu lato. In North America, the majority of human Lyme disease cases is caused by one species of these spirochetes, *B. burgdorferi* sensu stricto (*B. burgdorferi*),[3] whereas another species, *B. mayonii*, was recently identified to also cause human Lyme disease in the U.S.[4] A 2018 CDC study found that U.S. tickborne disease cases doubled from 2004 to 2016, with Lyme disease accounting for 82% of all reports.[5] Acute illness is commonly treated with antibiotics, but prolonged disease manifestations cost the U.S. health care system close to $1.3 billion a year (approximately $3000 per patient on average).[6] However, no effective Lyme disease prevention used prior to exposure to ticks is currently available.[7] Upon the tick bite, Lyme borreliae establish an infection in the skin at the bite site and disseminate through the bloodstream to distal tissues and organs, leading to manifestations including arthritis, carditis, and neuroborreliosis.[3,8] Such clinical observations support that spirochete attachment to host tissues is a requirement for the development of these manifestations.[9,10]

Vertebrate hosts generate multiple receptors on the cell surface that are exploited by microbes including Lyme borreliae to facilitate its tissue colonization.[9,11] One such receptor type is a proteoglycan (e.g., decorin and biglycan), which is composed of a core protein and covalently linked glycan chains, as known as glycosaminoglycans (GAGs).[12−14] Lyme borreliae less efficiently colonize the tissues of mice defective in producing decorin or biglycan.[15,16] These spirochetes were also documented to bind to these proteoglycans and several GAGs, including heparan sulfate and dermatan sulfate,[17−20] and the incubation of these molecules with Lyme borreliae inhibits spirochete attachment to the cells.[17,20] These results suggest that a spirochete's ability to bind to a proteoglycan or GAG mediates its attachment to host cells and tissues. Furthermore, *intravenous* inoculation of *B. burgdorferi* in conjunction with heparin, a GAG analog,

Received: November 9, 2019
Published: January 21, 2020

© 2020 American Chemical Society

https://dx.doi.org/10.1021/acsinfecdis.9b00425
ACS Infect. Dis. 2020, 6, 503−514



Figure 1. NACH bound to Lyme borreliae to prevent spirochete association with proteoglycans and GAGs. (A) Synthesis and structure of NACH: $m + n = 16$ for MW 12 kDa; R_1 = H or HSO_3; R_2 = Ac or HSO_3. (B) The percentage of *B. burgdorferi* strains B314, B31-A3, or 297, *B. afzelii* strains CB43 or VS461-JL, or *B. garinii* strains ZQ1 or PBr that bind to NACH or to BSA as a negative control was determined by ELISA (see the Methods section). Each bar represents the mean of four independent determinations ± standard deviation. Significant differences in spirochetal binding between indicated wells were determined using Mann−Whitney tests and are indicated (#, $P < 0.05$). (C−G) *B. burgdorferi* strains B314, B31-A3, or 297, *B. afzelii* strains CB43 or VS461-JL, or *B. garinii* strains ZQ1 or PBr were incubated with 2.5 mg mL^{-1} NACH or BSA alone as a negative control for 1 h prior to being added to microtiter plate wells immobilized with (C) decorin, (D) biglycan, (E) heparan sulfate ($HepSO_4$), (F) dermatan sulfate ($DermSO_4$), or (G) BSA (negative control). Each bar represents the mean of four independent determinations ± standard deviation. Significant reductions ($P < 0.05$) in spirochetal binding between different groups (#) or relative to BSA-treated spirochetes (*) are indicated using Mann−Whitney tests.

reduces the vascular interaction of spirochetes.[21,22] This result supports the use of heparin to prevent hematogenous dissemination of Lyme borreliae.

In fact, heparin has been examined as an antimicrobial therapeutic, since it is capable of modulating host immune responses against pathogens.[23] However, heparin has long been used as an anticoagulant to prevent clot formation; thus, this compound often triggers side effects such as thrombocytopenia and bleeding.[24,25] Additionally, the structure of unfractionated heparin is heterogeneous, and it has many chains, which appear to be associated with this heparin's short half-life in humans (<2 h).[26] These properties increase the complexity of using heparin to prevent microbial infection. A low molecular weight fraction of heparin (<8000 Da) has a prolonged half-life.[27−29] We and others have further modified the structure of low molecular weight heparin to eliminate its anticoagulant activity.[29,30] This non-anticoagulant version of low molecular weight heparin (NACH) demonstrates no toxicity in mammalian hosts and has been used in humans for clinical trials.[31−33] The improved pharmacology and safety of NACH raise the possibility of testing the ability of this compound to prevent Lyme disease infection.

In this study, we synthesized NACH, gave it to mice prior to exposure to ticks carrying *B. burgdorferi*, and examined the ability of NACH to prevent Lyme disease infection. We also investigated the mechanisms by which NACH blocked the infection onset and evaluated the possibility of using NACH as a pre-exposure prophylaxis (PrEP) for Lyme disease.

■ RESULTS

NACH bound to low passage Lyme borreliae strains and prevented these spirochetes from attaching to proteoglycans and GAGs.

Commercially available porcine intestinal heparin was treated with nitrous acid for depolymerization, resulting in the low molecular weight heparin, dalteparin (Figure 1A). This dalteparin was then oxidized with sodium periodate followed by $NaBH_4$ reduction as described in our previous work (Figure 1A).[29,30] The resulting product, NACH, was verified for its purity and low anticoagulant activity described in our recent study.[29] We next incubated the resulting NACH products or BSA (negative control) with different low passage and infectious Lyme borreliae species or strains, including *B. burgdorferi* strains B31-A3 and 297 (representing two

distinct genotypes associated with human infection),[34] *B. afzelii* strains CB43 and VS461-JL, and *B. garinii* strains ZQ1 and PBr. A high passage, noninfectious, and nonadherent *B. burgdorferi* strain B314 was also included as a negative control (Table S1).[35,36] The resulting spirochetes were added to the NACH-coated microtiter plate wells for the determination of spirochete attachment. Less than ten percent of these Lyme borreliae strains bound to BSA as expected (Figure 1B). While the negative control strain B314 bound to NACH at levels no different from that to BSA, more than 15% of other low passaged strains was immobilized by NACH at greater levels than that by BSA (Figure 1B). These results indicate the invariable ability of spirochete strains and species to attach to NACH.

NACH is an analog of heparin, which is structurally similar to the GAG component of proteoglycans binding Lyme borreliae. This raises the possibility that NACH is capable of inhibiting spirochetes binding to these proteoglycans and GAGs. Thus, we mixed NACH or PBS (negative control) with the above-mentioned Lyme borreliae strains and added the mixture into the microtiter plate wells immobilized with different proteoglycans and GAGs. These ligands included decorin, biglycan, heparan sulfate, and dermatan sulfate, and BSA was included as the control. As expected, the nonadherent strain B314 binds to these ligands at undetectable levels (lower than 10% binding) (Figure 1C−G). All infectious spirochete strains when treated with PBS bind to decorin, biglycan, heparan sulfate, and dermatan sulfate but not BSA at the levels greater than the strain B314 (Figure 1C−G). However, after being treated with NACH, these strains bind to the above-mentioned proteoglycans or GAGs no better than the strain B314 (Figure 1C−G), demonstrating that NACH has the ability to reduce spirochete attachment to proteoglycans and GAGs.

NACH Inhibited Spirochete Adhesion to Mammalian Cells. Since proteoglycans and GAGs are located on the surface of mammalian cells, we sought to determine the ability of NACH to block spirochete attachment to these cells. Different Lyme borreliae species or strains were thus incubated with NACH (or BSA, negative control) prior to being added to different mammalian cells types, including C6 glioma, SVEC endothelial, and SW982 joint synovial cells. These cell lines were selected as they were derived from the tissues that Lyme borreliae often colonize during infection. It is not surprising that less than 10% of the high passage and nonadherent strain B314 attaches to these cell types (Figure 2). After treatment with BSA, the infectious *B. burgdorferi*, *B. afzelii*, and *B. garinii* strains all bound to C6, SVEC, and SW982 cells at levels greater than the strain B314 (Figure 2). In contrast, treating these infectious Lyme borreliae strains with NACH resulted in lower levels of attachment to these cell lines, compared to the treatment of BSA (Figure 2). These findings show that NACH reduces Lyme borreliae attachment to mammalian cells.

NACH Reduced Spirochetes' Ability To Establish Infection in Mammalian Hosts. We next *intradermally* inoculated Swiss-Webster mice with NACH or PBS (negative control) to determine the ability of this compound to act as a PrEP in preventing Lyme disease infection (Figure S1). This mouse strain was used as it is outbred and thus more closely reflects the genetically variable background in humans. Additionally, this mouse strain has been commonly used as a model for mammalian Lyme disease infection.[37−39] Although comparable concentrations of chondroitin sulfate and hyaluronic acids were detected in NACH- and PBS-treated mice at 24 h post-inoculation, we observed greater levels of heparan sulfate in the NACH-treated mice (Table 1). This result is in agreement with the fact that heparan sulfate has a similar disaccharide unit to NACH,[29,30] and it also verifies the bioavailability of NACH through this inoculation route. Twenty four hours after administration, the *I. scapularis* nymphs carrying *B. burgdorferi* strains B31-A3 or 297 were allowed to feed on these mice until repletion (Figure S1). These mice were continuously inoculated daily in the same fashion with NACH until they were euthanized (Figure S1). The replete nymphs were weighed to evaluate their feeding quality, and the DNA extracted from the nymphs and tissues at different time points was collected to determine their bacterial burdens.

We found that the replete ticks feeding on NACH-inoculated mice do not weigh differently than the ticks feeding



Figure 2. NACH bound to Lyme borreliae to block the spirochetes' ability to attach to mammalian cells. *B. burgdorferi* strains B314 (negative control), B31-A3, or 297, *B. afzelii* strains CB43 or VS461-JL, or *B. garinii* strains ZQ1 or PBr were incubated with 2.5 mg mL^{-1} NACH or PBS alone as a negative control (none) for 1 h prior to being added to microtiter plate wells containing (A) C6 glioma, (B) SVEC endothelial, or (C) SW982 synovial cells or BSA (negative control, data not shown). Each bar represents the mean of four independent determinations ± standard deviation. Significant reductions ($P < 0.05$) in spirochetal binding relative to the strain B314 (*) or to BSA-treated spirochetes (#) are indicated using Mann−Whitney tests.

Table 1. Serum Concentration of NACH in Mice 24 h after Inoculation

	serum concentration of GAG (ng μL^{-1})[a]		
treatment	$HepSO_4$[b]	$ChonSO_4$[c]	hyaluronic acid
NACH	828.8 ± 1.06[d]	54 417 ± 1.19	561.6 ± 1.18
PBS	712.1 ± 1.03	51 758 ± 1.11	490.1 ± 1.29

[a]All values represent the geometric mean ± geometric standard deviation of seven (for NACH-treated mice) or five (for PBS-treated mice) mice per group. [b]Heparan sulfate. [c]Chondroitin sulfate. [d]Significantly greater value than heparan sulfate in the serum from PBS-treated mice using Mann−Whitney tests ($P = 0.0051$).

on PBS-administrated mice. This trend applied to the ticks carrying either B31-A3 or 297 strains (Figure S2A). These results indicate that NACH does not interfere with tick feeding. Compared to flat nymphs, the spirochete burdens in fully engorged nymphs increased approximately 10-fold, as reported previously (Figure S2B).[40,41] However, no differences in bacterial burdens were found in the strains B31- or 297-carrying nymphs feeding on NACH- or PBS-inoculated mice (Figure S2B). These observations show that NACH does not eliminate the spirochetes in ticks during feeding.

We also found that no spirochetes are detectable at the biting sites in the skin of PBS-inoculated and uninfected mice at 7 days post-tick feeding, as expected (Figure 3A). At this time point, the bacterial burdens of the PBS- or NACH-administrated mice fed on by ticks carrying the *B. burgdorferi* strain B31-A3 were greater than that in uninfected mice (Figure 3A). Between those infected mice, the spirochete loads were lower in NACH-treated individuals, compared to PBS-treated animals (Figure 3A). These results demonstrate the ability of NACH to reduce the infection establishment by Lyme borreliae in mammalian hosts. We were unable to detect the spirochetes at the heart, joints, ears, and bladder of PBS-inoculated and uninfected mice at 7 days post-tick feeding (Figure 3B−F). Similarly, the bacterial loads of either NACH- or PBS-treated animals were undetectable in these tissues, suggesting that *B. burgdorferi* has not disseminated to these distal tissues at 7 days post-tick feeding (Figure 3B−F).



Figure 3. Spirochetes were eliminated at tick biting sites of skin in NACH-treated mice. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying *B. burgdorferi* strain B31. NACH (or PBS) was given daily in the same fashion until the mice were euthanized. At 7 days post-tick feeding ("dpf"), mice were euthanized. The spirochete burdens in the (A) biting site of the skin ("Inoc. Site"), (B) tibiotarsus joints ("tibiotarsus"), (C) heart, (D) ears, (E) knee joints ("knees"), and (F) bladder. Bacterial burdens were determined by qPCR and normalized to 100 ng of total DNA. Uninfected, PBS-inoculated mice were included as the control ("-"). Shown are the geometric means ± geometric standard deviations of five mice per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal−Wallis test with Dunn's multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice ("*") or between two treatment groups ("#") are indicated.

NACH Facilitated *B. burgdorferi* Clearance at Tick Biting Sites and in the Bloodstream To Prevent Spirochete Dissemination to Distal Tissues. We sought to determine the burdens of the *B. burgdorferi* strain B31-A3 in tick biting sites at 14 days post-tick feeding. PBS-inoculated and uninfected mice did not develop detectable spirochete burdens at the biting site of the skin (Figure 4A). Although we were able to detect bacteria at this tissue and this time point from the PBS-inoculated and the strain B31-A3-infected mice, no spirochetes were detected at the biting site of the skin from NACH-inoculated mice (Figure 4A). Similarly, we also measured the spirochete burdens in tick biting sites of the skin at 56 days post-tick feeding and did not detect *B. burgdorferi* in this tissue of NACH-treated mice (Figure S3A). These results suggest that NACH inoculation promotes spirochete elimination at the infection-initiation site. Additionally, we were incapable of detecting spirochetes in the biting site of the skin from NACH-administrated mice at 56 days after these mice were fed on by ticks carrying the *B. burgdorferi* strain 297 (Figure S3A). This result suggests that such a NACH-mediated spirochete eradication at the tick biting sites can be extended to other Lyme borreliae strains.



Figure 4. Spirochetes could not disseminate to distal tissues in NACH-treated mice. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying *B. burgdorferi* strain B31. NACH (or PBS) was given daily in the same fashion until the mice were euthanized. At 14 days post-tick feeding ("dpf"), mice were euthanized. The spirochete burdens in the (A) biting site of the skin ("Inoc. Site"), (B) tibiotarsus joints ("tibiotarsus"), (C) heart, (D) ears, (E) knee joints ("knees"), and (F) bladder. Ears were determined by qPCR and normalized to 100 ng of total DNA. Uninfected, PBS-inoculated mice were included as the control ("-"). Shown are the geometric means ± geometric standard deviations of five mice per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal−Wallis test with Dunn's multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice ("*") or between two treatment groups ("#").

https://dx.doi.org/10.1021/acsinfecdis.9b00425
ACS Infect. Dis. 2020, 6, 503−514

We also determined the burdens of the *B. burgdorferi* strain B31-A3 in the heart, joints, ears, and bladder at 14 days post-tick feeding. While spirochetes were undetectable in these tissues of PBS-inoculated and uninfected mice, approximately 10^3 of the strain B31-A3 were found to colonize at the heart, joints, ears, and bladder of mice administrated with PBS and fed on by ticks carrying this spirochete strain (Figure 4B–F). Interestingly, no bacteria were detected at these distal tissues of NACH-administrated mice followed by being infected using ticks carrying the strain B31-A3 (Figure 4B–F). Similar trends of undetectable colonization at the joints, heart, ears, and bladder were found in NACH-treated mice at 56 days post-feeding (Figure S3B–F). These observations suggest that NACH-treatment prevents spirochete dissemination to distal tissues. Further, we did not observe the colonization of any spirochetes at these tissues of NACH-treated mice when mice were infected with *B. burgdorferi* strain 297 (Figure S3B–F). These results clearly point out the ability of NACH to prevent multiple Lyme borreliae strains' dissemination.

The fact that Lyme borreliae dissemination requires the ability to survive in the bloodstream raises the possibility that NACH may facilitate hematogenous clearance of spirochetes, preventing dissemination. Thus, we determined the spirochete burdens in the mouse bloodstream at different time points after tick feeding. The *B. burgdorferi* strain B31-A3 survived at indistinguishable levels in the bloodstream of PBS- or NACH-treated mice at 4 days post-tick feeding (Figure 5A). However, compared to PBS-treated mice where the strain B31-A3 survival was close to being uninfluenced, the burdens of this strain in NACH-treated mice were reduced at 7 days and undetectable at 10 days post-feeding (Figure 5B,C). Fourteen days after tick feeding, we were unable to detect the spirochetes in the bloodstream of either PBS-inoculated or NACH-treated mice (Figure 5D). This result is in agreement with the adaptive immune clearance of Lyme borreliae in the bloodstream at this time point.[42,43] Taken together, these findings indicate faster kinetics of the hematogenous clearance of *B. burgdorferi* in NACH-treated mice.



Figure 5. Spirochetes were cleared from the bloodstream of the NACH-treated mice at an earlier onset than that of PBS-treated mice. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying the *B. burgdorferi* strain B31. NACH (or PBS) was give daily in the same fashion until the mice were euthanized. The spirochete burdens in the bloodstream were determined by qPCR and normalized to 100 ng of total DNA at (A) 4 , (B) 7 , (C) 10 , or (D) 14 days post-tick feeding ("dpf"). Uninfected and PBS-inoculated mice were included as the control ("-"). Shown are the geometric means ± geometric standard deviations of seven (for 7 dpf NACH-treated mice), ten (for 7 dpf, PBS-treated mice) or five mice (for the other time points) per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal–Wallis test with Dunn's multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice ("*") or between two treatment groups ("#") are indicated.

NACH-Treated Mice Developed More Robust Early Antibody Immune Responses against Spirochetes after Lyme Disease Infection. Our finding that *B. burgdorferi* is more rapidly eliminated in NACH-treated mice than in PBS-inoculated mice leads to the possibility that NACH facilitates spirochete clearance. However, we found that the number of motile *B. burgdorferi* strains B31-A3 or 297 does not decrease after the treatment of NACH, similar to these strains treated with PBS (data not shown). Additionally, both strains treated with NACH had doubling times (generation time) no different than those treated with PBS (Table S2). These results indicate that NACH does not directly kill Lyme borreliae. As antibody responses play a key role to clear Lyme borreliae during infection, we next sought to examine whether such immune responses are modulated by NACH. Mice were given NACH (or PBS) 1 day prior to the exposure to ticks carrying the *B. burgdorferi* strain B31-A3 and were continuously administered NACH daily after infection. Blood was collected at different time points to examine for the levels of IgG and IgM against spirochetes. As expected, IgM titers in infected mice treated with either NACH or PBS were no greater than that in uninfected mice at 4 days post-tick feeding (Figure 6A). The mice fed on by nymphs under either treatment developed greater titers of IgM than the uninfected mice at 7, 10, and 14 days post-tick feeding, indicating that both mice were infected by *B. burgdorferi* (Figure 6B–D). However, while the IgM levels of PBS-treated and *B. burgdorferi*-infected mice remained higher than that in uninfected mice at 21 and 56 days post-feeding, antibody levels of infected mice treated with NACH were no different from that in uninfected mice (Figure 6E,F). These results are consistent with the fact that spirochetes are cleared from tissues and bloodstream at those time points in NACH-treated mice (Figures 4, 5, and S3). Interestingly, after infection, NACH-treated mice developed greater IgM titers than PBS-inoculated mice at 7 days post-tick feeding. This result suggests that NACH triggers efficient IgM responses at early stages of infection (Figure 6B).

Similarly, all the mouse groups did not generate detectable titers of IgG at 4 days post-feeding (Figure 6G). The infected mice under either NACH or PBS treatment developed greater IgG titers than the uninfected mice at 10, 14, and 21 days post-feeding (Figure 6I–K). The IgG titers of NACH-treated, *B. burgdorferi*-infected mice were lower than that in PBS-inoculated, spirochete-infected mice at 21 days post-tick feeding and undetectable at 56 days post-tick feeding (Figure 6K,L). These data are in agreement with the elimination of *B. burgdorferi* in NACH-treated mice at these time points. Similar to IgM, the IgG titers in infected mice treated with NACH were greater than that in the infected mice treated with PBS at 7 days post-tick feeding (Figure 6H). These results suggest the ability of NACH to induce early IgG responses. Taken together, these observations indicate that NACH administration triggers robust antibody immune responses against spirochetes early during Lyme disease infection.

https://dx.doi.org/10.1021/acsinfecdis.9b00425
ACS Infect. Dis. 2020, 6, 503–514



Figure 6. Mice administrated with NACH developed more robust antibodies against spirochetes than PBS-treated mice at the early stages of infection. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying the *B. burgdorferi* strain B31-A3. NACH (or PBS) was given daily in the same fashion until the mice were euthanized. The sera were obtained at (A and G) 4, (B and H) 7, (C and I) 10, (D and J) 14, (E and K) 21, and (F and L) 56 days post-tick feeding ("dpf"). Uninfected and PBS-inoculated mice were included as the control ("-"). The levels of IgG (A−F) and IgM (G−L) against the *B. burgdorferi* strain B31-A3 were determined using quantitative ELISA as described in the Methods section. Shown are the geometric means ± geometric standard deviations of five mice per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal−Wallis test with Dunn's multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice ("*") or between two treatment groups ("#") are indicated.

DISCUSSION

Lyme borreliae bind to GAGs and proteoglycans,[17−20] and such binding activity facilitates spirochete attachment to mammalian cells/tissues under static[35,44−47] or shear stressed conditions.[20−22,48−50] Among those ligands, decorin, biglycan, and dermatan sulfate were reported to bind to spirochetes, promoting tissue colonization of spirochetes and Lyme disease-associated manifestations.[15,16,51−53] We found that Lyme borreliae species and strains display a universal capability of binding to NACH, an analog of GAGs. We also demonstrated that NACH-treated spirochetes display reduced binding ability to different purified GAGs and proteoglycans, compared to untreated bacteria. Our findings raise a possibility that NACH blocks spirochete binding to GAGs and proteoglycans, inhibiting the colonization and disease manifestations caused by Lyme borreliae infection. This notion is supported by our observation of less efficient spirochete colonization at inoculation sites and distal tissues in the mice treated with NACH, compared to negative control mice. Further, such GAG- and proteoglycan-binding activities of Lyme borreliae have been attributed to several GAG- and/or proteoglycan-binding proteins on the surface of spirochetes.[44,45,51,54−56] Additionally, spirochetes deficient of some of these GAG- and proteoglycan-binding outer surface proteins less efficiently colonize at tissue and trigger manifestations than the parental wild-type strain.[47,52,53] Thus, our finding of NACH's efficacy to prevent spirochete colonization leads to an intriguing question: Does NACH target these Lyme borreliae outer surface proteins to inhibit dissemination? Such a question warrants further investigations.

Vertebrate animals develop innate immune responses to eradicate Lyme borreliae immediately after spirochetes invade these hosts, which serve as a bottleneck prior to the infection establishment.[57−61] Adaptive immune responses are activated later, which control spirochete burdens, resulting in reduced and persistent colonization at the tissues.[62−65] Specifically, the levels of antibodies against Lyme borreliae or their outer surface antigens in sera have been correlated with the spirochete loads at the tissues, supporting the role of B cell responses in mediating Lyme borreliae clearance.[66,67] Therefore, a more robust antibody production at the earlier infection onset would be expected to facilitate a more efficient clearance of spirochetes. Such effective eradication could then prevent spirochete dissemination to and colonization at distal tissues. In fact, we found that mice inoculated with NACH followed by being infected with Lyme borreliae develop greater levels of IgG and IgM against spirochetes at early stages of infection. These results are supported by the previous findings showing that low molecular weight heparin is capable of modulating host immune responses, resulting in more efficient elimination of pathogenic bacteria by mammalian hosts.[23] Additionally, the kinetics of NACH-mediated robust antibody production match the onset of spirochete eradications at tick biting sites and in the bloodstream. This coincidence suggests that high levels of antibody generation against spirochetes at early stages of infection are likely one of the mechanisms for NACH to prevent Lyme disease infection.

In this study, we could not detect spirochetes at 56 days post-tick feeding when NACH was given to the mice prior to the exposure to ticks carrying Lyme borreliae and introduced daily after infection. Six different tissues previously shown to be colonized by Lyme borreliae after tick feeding were included. These results do not rule out the possibility that spirochetes remain and colonize other untested tissues. However, that scenario is unlikely because of the decreasing numbers of antibodies against spirochetes from 14 to 21 days after tick feeding and the seronegative results at 56 days post-tick feeding in NACH-treated mice. Furthermore, antibiotics are available as prophylaxis to prevent Lyme disease immediately after tick exposure.[68] However, the fact that many people do not notice a tick bite addresses the need of the prevention prior to tick infection. The only currently developed PrEP is a monoclonal antibody, which blocks tick-to-host transmission of Lyme borreliae by targeting a spirochete outer surface protein, OspA.[69] Unlike that prophylaxis, NACH targets GAG/proteoglycan-binding activity and upregulates antibody immune responses, which are not Lyme borreliae-specific. Thus, NACH may be potentially extended to prevent the infection caused by other pathogens.

■ CONCLUSION

Our results highlight the potential of using NACH as a PrEP to prevent Lyme disease infection, but it is noted that the intradermal route and a comparatively short half-life of the NACH regimen used in this study (~12 h) may not be ideal for PrEP development.[33] Many excipients have been used to formulate heparin to enhance the oral bioavailability and increase the half-life.[70−74] These findings shed light on the further development of NACH as a more suitable compound for human use as Lyme disease PrEP. Additionally, the oral administration of prevention by targeting the reservoir animals has been examined as a strategy to reduce the risk of exposure to Lyme borreliae.[75−78] Thus, our findings also provide a possibility to use NACH as a bait for reservoir hosts in Lyme disease prevention through the formulation to enhance oral bioavailability and half-life. In this proof-of-concept study, we examined the possibility of using NACH prior to tickborne Lyme borreliae transmission to prevent spirochete colonization. We also investigated the potential mechanisms that drive NACH-mediated protection against Lyme disease. The results derived from this study will provide the foundation to ultimately enable us to reduce the burdens of human Lyme disease.

■ METHODS

Ethics Statement. All mouse experiments were performed in strict accordance with all provisions of the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the PHS Policy on Humane Care and Use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee of Wadsworth Center, New York State Department of Health (protocol Docket Number 19-451). All efforts were made to minimize animal suffering.

Mouse, Ticks, Bacterial Strains, Antisera, and Enzymes. Swiss-Webster mice were purchased from Taconic (Hudson, NY). *Ixodes scapularis* tick larvae were obtained from BEI Resources (Manassas, VA). *B. burgdorferi*-infected nymphs were generated as described in Generation of Nymphal Ticks Carrying *B. burgdorferi*. All *B. burgdorferi*, *B. afzelii*, and *B. garinii* strains used in this study were grown in BSK-II complete medium (Table S1). To generate the antisera against different Lyme borreliae species, *B. burgdorferi* strain B31-A3, *B. afzelii* strain VS461-JL, or *B. garinii* strain ZQ1 was *intradermally* introduced into mice (10^6 bacteria per mouse). At 21 days post-infection, an ear biopsy (one biopsy per mouse) was collected to determine the infectivity of the particular strain used to infect that mouse using quantitative PCR (qPCR; see Quantitative PCR and the previous description[53]). Sera were collected from the qPCR-positive mice, and its seropositivity was verified for the particular strain used to infect that mouse using ELISA as described previously.[79] Chondroitin lyase ABC from *Proteus vulgaris* was expressed in our laboratory. Recombinant *Flavobacterial* heparin lyases I, II, and III were expressed in our laboratory previously.[80]

Production, Purification, and Verification of NACH. NACH was synthesized from the low molecular weight heparin, dalteparin, through nitrous acid depolymerization of porcine intestinal heparin, followed by periodate oxidation as described in our previous work.[29,30] Briefly, one gram of dalteparin (>95% purity) in aqueous solution (8.75 mL, pH 5.0) was added to a freshly prepared 140 mM $NaIO_4$ solution (25 mL, pH 5.0) in a single portion with stirring. The oxidation was carried out at 4 °C for 24 h in the dark before the solution was desalted using 3 kDa cutoff spin columns. $NaBH_4$ (50 mg) was added to the reaction to reduce the generated aldehydes. NACH was precipitated by adding ethanol to 80% (v/v). The final NACH product (>95% purity) was obtained by desalting and lyophilization. The structure of NACH was confirmed by NMR with the average MWs (~3870 Da) measured by gel permeation chromatography (GPC). A very low anticoagulant activity (6 U/mg as anti-Xa potency) of NACH was detected by using a BIOPHEN heparin anti-Xa (2 stages) kit (Aniara Diagnostica, West Chester, OH). GPC and disaccharide analysis confirmed the >95% purity of NACH using USP enoxaparin as a standard.

Determining the Serum Concentration of GAGs Derived from NACH. Mice were *intradermally* injected with NACH (5 mg per kg of mouse), and sera were collected from these mice at 24 h post-inoculation. The determination of GAG composition in the sera has been described previously.[81,82] Basically, 20 μL of sera was loaded onto a spin column (molecular weight cutoff of 3 kDa),[76] and then, the column was washed with distilled water. The upper solution was mixed with 300 μL of digestion buffer[76] and a mixture of GAG lyases, including heparin lyase I, II, and III as well as chondroitin lyase ABC (10 mU for each GAG lyase). After incubation at 37 °C overnight, the reaction mixture was applied to a spin column with a molecular weight cutoff of 3 kDa to terminate the reaction by GAG lyases. After air-drying the flow through, the sample was labeled with 2-aminoacridone (AMAC) by being incubated with 10 μL of AMAC (0.1 M, Sigma-Aldrich) in DMSO/acetic acid (17/3, V/V, Sigma-Aldrich) at room temperature for 10 min, followed by being mixed with 10 μL of $NaBH_3CN$ (1 M) at 45 °C for 1 h. The resulting samples were spun down, and the supernatant was collected and stored in a light resistant container at room temperature until analysis via LC-MS/MS.

LC was performed on an Agilent 1200 LC system at 45 °C using an Agilent Poroshell 120 ECC18 (2.7 μm, 3.0 × 50 mm) column (Agilent Technology, Santa Clara, CA). The mobile phases A (MPA) and B (MPB) were ammonium acetate (50

mM) and methanol, respectively. The gradient used for purification was 5% to 45% MPB/95 to 55% MPA from 0 to 10 min, 45% to 100% MPB/55% to 0% MPA from 10 to 10.2 min, 100% MPB/0% MPA from 10.2 to 14 min, 100% to 5% MPB/0% to 95% MPA from 14 to 22 min. The flow rate was 300 μL per minute. A triple quadrupole mass spectrometry system equipped with an ESI source (Thermo Fisher Scientific, San Jose, CA) was used as the detector. The online MS analysis was at the multiple reaction monitoring (MRM) mode. The parameters for MS analysis are as follows: negative ionization mode with a spray voltage of 3000 V, a vaporizer temperature of 300 °C, and a capillary temperature of 270 °C.

Binding of Spirochetes to NACH. One hundred microliters of NACH or BSA (negative control) at a concentration of 1 mg mL^{-1} in the coating buffer (0.1 M carbonate/bicarbonate, pH 9.6[51]) was added to ELISA microtiter plate wells (ThermoScientific, Pittsburgh, PA). The plates were then incubated for 16 h at 4 °C followed by being blocked using 5% PBS−BSA. Spirochetes suspended in BSK-H medium were added to wells with the immobilized NACH at 1×10^6 spirochetes per well. To enhance spirochete cell contact, the plates were centrifuged at 106*g* for 5 min and then rocked at room temperature for 1 h. Unbound bacteria were removed by washing with PBS containing 0.2% BSA. To generate the plate wells with bacteria for the purpose of normalization, spirochetes (1×10^6 per well) suspended in the coating buffer were added to the plate wells. Immobilized Lyme borreliae or the spirochetes bound on NACH (or BSA) were fixed using 3% paraformaldehyde followed by 100% chilled methanol. After the plates were air-dried, the antisera against *B. burgdorferi*, *B. afzelii*, or *B. garinii* (1:200×) and HRP-conjugated goat antimouse IgG (ThermoFisher; 1:2000×) were used as primary and secondary antibodies, respectively. The plates were washed three times with PBST (0.05% Tween 20 in PBS), and 100 μL of tetramethylbenzidine solution (ThermoFisher) was added to each well; the wells were incubated for 5 min. The reaction was stopped by adding 100 μL of 0.5% hydrosulfuric acid to each well. The absorption at 405 nm of each well was obtained by reading the plates at that wavelength using a Tecan Sunrise Microplate reader (Tecan, Morrisville NC). The percent binding of spirochetes was derived from the absorption values of spirochete attachment to each well normalized to the values obtained from the wells immobilized with 1×10^6 of those spirochetes.

Inhibition of Proteoglycan, GAG, and Mammalian Cell Binding with Exogenous NACH. One hundred microliters of human decorin (gifts from Drs. David Mann and Nancy Ulbrandt), human biglycan (Sigma-Aldrich, St. Louis, MO), heparin sulfate (Sigma-Aldrich), porcine dermatan sulfate (Millipore Billerica, MA), or BSA (negative control) at a concentration of 1 mg mL^{-1} in the coating buffer was added to ELISA microtiter plate wells. The plates were then incubated for 16 h at 4 °C followed by being blocked using 5% PBS−BSA. For the plate wells cultivated with mammalian cells, C6 rat glioma, SVEC rat endothelial, or SW982 human synovial cells (gifts provided by Dr. John Leong) were added into microtiter plate wells (1×10^5 per well). Spirochetes (1×10^6) were prepared as described in "Binding of Spirochetes to NACH" and incubated for 30 min at room temperature in BSK-H supplemented with 1 mg mL^{-1} NACH. Spirochetes were then added into these proteoglycans- or GAGs-coated plate wells and incubated at room temperature for 1 h. The percent binding of spirochetes was determined as described earlier.

Determination of Spirochete Killing Activity of NACH *in Vitro*. We evaluated the viability of NACH-treated spirochetes with a survival assay and growth curve. To determine the spirochetes' viability, 10^6 *B. burgdorferi* strains B31-A3 or 297 in BSK-II complete were treated with PBS buffer or 100 μg of NACH in this buffer and incubated at 33 °C in triplicate. The motility of the bacteria as determined as viable cells was observed initially and again after 24 h using dark field microscopy by evaluating four fields of view.[83] The percentage of motile spirochetes was determined as described.[40,83] These spirochetes were then seeded in BSK II medium, also in triplicate, to determine the spirochetes' generation time as previously described.[84]

Generation of Nymphal Ticks Carrying *B. burgdorferi*. The experimental procedure has been described previously.[40] Basically, four week-old male and female C3 deficient BALB/c mice were infected with 10^5 of the *B. burgdorferi* strain B31-A3 or 297 by intradermal injection (1×10^5 spirochetes per mouse). The plasmid profiles of strain B31-A3 were verified prior to infection as described to ensure no loss of plasmids.[85−87] The strain 297 was maintained at passages less than ten. The ear punches from those mice were collected and examined in the presence of spirochete DNA at 7 days post-infection using qPCR as described to confirm the infection of these mice.[40] At 14 days post-infection, the uninfected *I. scapularis* larvae were allowed to feed to repletion on those *B. burgdorferi*-infected mice as described previously.[40] Approximately 100 to 200 larvae were allowed to feed on each mouse. The engorged larvae were collected and allowed to molt into nymphs in 4 to 6 weeks in a desiccator at room temperature and 95% relative humidity in a room with light−dark control (light to dark, 12:12 h).

NACH Inoculation and *B. burgdorferi* Infection via Ticks. Four week-old female Swiss-Webster mice were *intradermally* inoculated with NACH in PBS (5 mg per kg of mouse) or PBS (control). The tick infection procedure was described previously.[40] Basically, at 24 h post-inoculation, ten nymphs were allowed to feed on each mouse until repletion, and replete nymphs were collected for weight measurement. After placing nymphs on those mice, these mice were continuously given NACH or PBS daily in the same fashion. Uninfected and PBS-inoculated mice were included as negative controls. Blood was collected at 4, 7, 10, and 14 days post-tick feeding whereas sera were obtained at 4, 7, 10, 14, 21, and 56 days post-tick feeding. Mice were euthanized at 7, 14, and 56 days after tick feeding, and the feeding sites of the skin, the tibiotarsus and knee joints, heart, ears, and bladder were collected. Animal tissues, blood, and ticks were used to quantitatively evaluate the levels of colonization during infection (see Quantitative PCR) while sera were used to measure the levels of antibodies (see Quantification of Antibody Titers against *B. burgdorferi*).

Quantitative PCR. DNA was extracted using an EZ-10 Spin Column Blood DNA Mini-Prep Kit (BioBasic, Inc., Markham, Ontario, Canada). The quantity and quality of DNA for each tissue, tick, or blood sample were assessed by measuring the concentration of DNA and the ratio of the UV absorption at 260 to 280 nm using a Nanodrop 1000 UV/vis spectrophotometer (ThermoFisher, Waltham, MA). The 280:260 ratio was between 1.75 and 1.85, indicating the lack of contaminating RNA or proteins. qPCR was performed to

https://dx.doi.org/10.1021/acsinfecdis.9b00425
ACS Infect. Dis. 2020, 6, 503−514

quantify spirochete loads through the amplification of the *16s rRNA* gene (Table S3).[88] The reactions were performed with the instrument and reagent as described.[83] Cycling parameters for the *16s rRNA* gene were 50 °C for 2 min, 95 °C for 10 min, 45 cycles of 95 °C for 15 s, and 60 °C for 1 min. Each biological replicate was performed in duplicate due to the potential variation of these runs. The number of *16s rRNA* copies was calculated by fitting the established threshold cycle (Cq) standard curve of a known number of the *16s rRNA* genes extracted from the cultivated respective spirochete strains. Five samples from each tissue were also applied to qPCR using mouse nidogen primers to ensure that low signals of the results were not due to the presence of PCR inhibitors (Table S3).[53,89] 10^7 copies of the mouse nidogen gene from 100 ng of each DNA sample were detected as predicted, ruling out the presence of PCR inhibitors in these samples.

Quantification of Antibody Titers against *B. burgdorferi*. The measurement of IgG and IgM titers against spirochete strains was performed using ELISA. In brief, microtiter plate wells were coated with the *B. burgdorferi* strains B31 or 297 (1×10^6 spirochetes per well). After blocking with 5% PBS−BSA, mouse serum diluted in 50 μL of PBS (1:100×, 1:300×, or 1:900×) was added to each well. The antibodies and the reading protocol of the equipment have been described.[83] We determined the titers by obtaining the greatest maximum slope of optical density/min per sample. The values of such maximum slopes were multiplied by the respective serum dilution factor as shown as arbitrary units.

Statistical Analysis. Significant differences between the samples were determined using the Kruskal−Wallis test with Dunn's multiple comparison or the Mann−Whitney test. A *P* value of <0.05 was considered to be significant.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.9b00425.

> Experimental timeline of NACH inoculation and tick infection in mice (Figure S1); replete ticks acquiring blood from NACH- or PBS-treated mice displaying similar weight and spirochete burdens (Figure S2); spirochetes being undetectable at 56 days post-tick feeding of NACH-treated mice (Figure S3); strains used in this study (Table S1); the generation time of PBS- and NACH-treated *B. burgdorferi* strains used in this study (Table S2); primers used in this study (Table S3) (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Yi-Pin Lin − *Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States; Department of Biomedical Sciences, State University of New York at Albany, Albany, New York 12222, United States;* orcid.org/0000-0002-5240-2031; Email: Yi-Pin.Lin@health.ny.gov

Robert J. Linhardt − *Department of Chemical and Biological Engineering, Department of Chemistry and Chemical Biology, and Departments of Biology and Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180, United States;* orcid.org/0000-0003-2219-5833; Email: linhar@rpi.edu

Authors

Yanlei Yu − *Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States*

Ashley L. Marcinkiewicz − *Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States*

Patricia Lederman − *Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States*

Thomas M. Hart − *Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States; Department of Biological Science, State University of New York at Albany, Albany, New York 12222, United States*

Fuming Zhang − *Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States;* orcid.org/0000-0003-2803-3704

Complete contact information is available at: https://pubs.acs.org/10.1021/acsinfecdis.9b00425

Author Contributions

Conceptualization: Y.-P.L., F.Z., and R.J.L. Data curation: Y.-P.L., Y.Y., A.L.M., P.L., and T.M.H. Formal analysis: Y.-P.L., Y.Y., A.L.M., F.Z., and R.J.L. Funding acquisition: Y.-P.L., F.Z., and R.J.L. Investigation: Y.-P.L., Y.Y., A.L.M., P.L., T.M.H., F.Z., and R.J.L. Methodology: Y.-P.L., Y.Y., A.L.M., P.L., T.M.H., F.Z., and R.J.L. Project administration: Y.-P.L. and R.J.L. Resources: Y.-P.L., F.Z., and R.J.L.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Jennifer Yates and Wen-Yi Li for valuable advice on the experimental design and Amber Frye for technical assistance. We also thank John Leong, Ryan Rego, and Peter Kraiczy for providing *B. burgdorferi* strains B31-A3, B314, and 297, *B. afzelii* strains CB43 and VS461-JL, and *B. garinii* strains ZQ1 and PBr. Additionally, we thank Jian Liu for providing the *E. coli* strains producing recombinant heparin lyase I, II, and III, David Mann and Nancy Ulbrandt (MedImmune, Inc., Gaithersburg, MD) for providing recombinant decorin, John Leong for providing SVEC endothelial, SW982 synovial, and C6 glial cells, and Media & Tissue Culture Core in Wadsworth Center for preparation of the *Borrelia* culture medium. This work was supported by NSF-IOS1755286 (to Y.-P.L., A.L.M., P.L., and T.M.H.), DoD-TB170111 (to Y.-P.L., A.L.M., P.L., and T.M.H.), a New York State Department of Health Wadsworth Center Start-Up Grant (to Y.-P.L., A.L.M., P.L., and T.M.H.), and NIH-DK111958 (to Y.Y., F.Z., and R.J.L.).

■ ABBREVIATIONS

LD, Lyme disease; PrEP, pre-exposure prophylaxis; PG, proteoglycan; GAG, glycosaminoglycan; NACH, non-anticoagulant heparin; *Bbsl*, *Borrelia burgdorferi* sensu lato; *B. burgdorferi*, *B. burgdorferi* sensu stricto; $HepSO_4$, heparan sulfate; $ChonSO_4$, chondroitin sulfate; $DermSO_4$, dermatan sulfate; *Bb*, *B. burgdorferi*; *Ba*, *B. arzelii*; *Bg*, *B. garinii*; dpf, days post-tick feeding; MRM, multiple reaction monitoring; TMB, tetramethylbenzidine; AU, arbitrary unit

■ REFERENCES

(1) Brisson, D., Drecktrah, D., Eggers, C. H., and Samuels, D. S. (2012) Genetics of *Borrelia burgdorferi*. *Annu. Rev. Genet. 46*, 515−36.

(2) Rosa, P. A., Tilly, K., and Stewart, P. E. (2005) The burgeoning molecular genetics of the Lyme disease spirochaete. *Nat. Rev. Microbiol. 3* (2), 129−43.

(3) Steere, A. C., Strle, F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W., Li, X., and Mead, P. S. (2016) Lyme borreliosis. *Nature reviews. Disease primers 2*, 16090.

(4) Pritt, B. S., Mead, P. S., Johnson, D. K. H., Neitzel, D. F., Respicio-Kingry, L. B., Davis, J. P., Schiffman, E., Sloan, L. M., Schriefer, M. E., Replogle, A. J., Paskewitz, S. M., Ray, J. A., Bjork, J., Steward, C. R., Deedon, A., Lee, X., Kingry, L. C., Miller, T. K., Feist, M. A., Theel, E. S., Patel, R., Irish, C. L., and Petersen, J. M. (2016) Identification of a novel pathogenic *Borrelia* species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. *Lancet Infect. Dis. 16* (5), 556−564.

(5) Rosenberg, R., Lindsey, N. P., Fischer, M., Gregory, C. J., Hinckley, A. F., Mead, P. S., Paz-Bailey, G., Waterman, S. H., Drexler, N. A., Kersh, G. J., Hooks, H., Partridge, S. K., Visser, S. N., Beard, C. B., and Petersen, L. R. (2018) Vital Signs: Trends in Reported Vectorborne Disease Cases - United States and Territories, 2004−2016. *MMWR. Morbidity and mortality weekly report 67* (17), 496−501.

(6) Adrion, E. R., Aucott, J., Lemke, K. W., and Weiner, J. P. (2015) Health care costs, utilization and patterns of care following Lyme disease. *PLoS One 10* (2), e0116767.

(7) Gomes-Solecki, M., Arnaboldi, P. M., Backenson, P. B., Benach, J. L., Cooper, C. L., Dattwyler, R. J., Diuk-Wasser, M., Fikrig, E., Hovius, J. W., Laegreid, W., Lundberg, U., Marconi, R. T., Marques, A. R., Molloy, P., Narasimhan, S., Pal, U., Pedra, J. H. F., Plotkin, S., Rock, D. L., Rosa, P., Telford, S. R., Tsao, J., Yang, X. F., and Schutzer, S. E. (2019) Protective Immunity and New Vaccines for Lyme Disease. *Clin. Infect. Dis.*, DOI: 10.1093/cid/ciz872.

(8) Radolf, J. D., Caimano, M. J., Stevenson, B., and Hu, L. T. (2012) Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. *Nat. Rev. Microbiol. 10* (2), 87−99.

(9) Coburn, J., Leong, J., and Chaconas, G. (2013) Illuminating the roles of the *Borrelia burgdorferi* adhesins. *Trends Microbiol. 21* (8), 372−9.

(10) Hyde, J. A. (2017) Borrelia burgdorferi Keeps Moving and Carries on: A Review of Borrelial Dissemination and Invasion. *Front. Immunol. 8*, 114.

(11) Chagnot, C., Listrat, A., Astruc, T., and Desvaux, M. (2012) Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components. *Cell. Microbiol. 14* (11), 1687−96.

(12) Kamhi, E., Joo, E. J., Dordick, J. S., and Linhardt, R. J. (2013) Glycosaminoglycans in infectious disease. *Biological reviews of the Cambridge Philosophical Society 88* (4), 928−43.

(13) Lin, Y. P., Li, L., Zhang, F., and Linhardt, R. J. (2017) *Borrelia burgdorferi*glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease. *Microbiology 163* (12), 1759−1766.

(14) Lin, Y.-P., Osburne, M., Pereira, M., Coburn, J., and Leong, J. M. (2016) *Glycosaminoglycan Binding by the Lyme Disease Spirochete is a Determinant of Tissue Tropism and Disease*, 1 ed., p 334, CRC Press.

(15) Brown, E. L., Wooten, R. M., Johnson, B. J., Iozzo, R. V., Smith, A., Dolan, M. C., Guo, B. P., Weis, J. J., and Hook, M. (2001) Resistance to Lyme disease in decorin-deficient mice. *J. Clin. Invest. 107* (7), 845−52.

(16) Cuellar, J., Pietikainen, A., Glader, O., Liljenback, H., Soderstrom, M., Hurme, S., Salo, J., and Hytonen, J. (2019) *Borrelia burgdorferi* Infection in Biglycan Knockout Mice. *J. Infect. Dis. 220* (1), 116−126.

(17) Leong, J. M., Wang, H., Magoun, L., Field, J. A., Morrissey, P. E., Robbins, D., Tatro, J. B., Coburn, J., and Parveen, N. (1998) Different classes of proteoglycans contribute to the attachment of *Borrelia burgdorferi* to cultured endothelial and brain cells. *Infect. Immun. 66* (3), 994−9.

(18) Parveen, N., Robbins, D., and Leong, J. M. (1999) Strain variation in glycosaminoglycan recognition influences cell-type-specific binding by lyme disease spirochetes. *Infection and immunity 67* (4), 1743−1749.

(19) Guo, B. P., Norris, S. J., Rosenberg, L. C., and Hook, M. (1995) Adherence of *Borrelia burgdorferi*to the proteoglycan decorin. *Infection and immunity 63* (9), 3467−72.

(20) Salo, J., Pietikainen, A., Soderstrom, M., Auvinen, K., Salmi, M., Ebady, R., Moriarty, T. J., Viljanen, M. K., and Hytonen, J. (2016) Flow-Tolerant Adhesion of a Bacterial Pathogen to Human Endothelial Cells Through Interaction With Biglycan. *J. Infect. Dis. 213* (10), 1623−31.

(21) Moriarty, T. J., Norman, M. U., Colarusso, P., Bankhead, T., Kubes, P., and Chaconas, G. (2008) Real-time high resolution 3D imaging of the lyme disease spirochete adhering to and escaping from the vasculature of a living host. *PLoS Pathog. 4* (6), e1000090.

(22) Norman, M. U., Moriarty, T. J., Dresser, A. R., Millen, B., Kubes, P., and Chaconas, G. (2008) Molecular mechanisms involved in vascular interactions of the Lyme disease pathogen in a living host. *PLoS Pathog. 4* (10), e1000169.

(23) Sharma, L., Wu, J., Patel, V., Sitapara, R., Rao, N. V., Kennedy, T. P., and Mantell, L. L. (2014) Partially-desulfated heparin improves survival in *Pseudomonas* pneumonia by enhancing bacterial clearance and ameliorating lung injury. *J. Immunotoxicol. 11* (3), 260−7.

(24) Oduah, E. I., Linhardt, R. J., and Sharfstein, S. T. (2016) Heparin: Past, Present, and Future. *Pharmaceuticals 9* (3), 38.

(25) Hirsh, J. (1984) Heparin induced bleeding. *Nouv. Rev. Fr. Hematol. 26* (4), 261−266.

(26) Mohamed, S., and Coombe, D. R. (2017) Heparin Mimetics: Their Therapeutic Potential. *Pharmaceuticals 10* (4), 78.

(27) Boneu, B., Caranobe, C., and Sie, P. (1990) Pharmacokinetics of heparin and low molecular weight heparin. *Baillieres Clin Haematol 3* (3), 531−44.

(28) Alban, S., Welzel, D., and Hemker, H. C. (2002) Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH. *Semin. Thromb. Hemostasis 28* (4), 369−78.

(29) Ouyang, Y., Yu, Y., Zhang, F., Chen, J., Han, X., Xia, K., Yao, Y., Zhang, Z., and Linhardt, R. J. (2019) Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications. *J. Med. Chem. 62* (2), 1067−1073.

(30) Islam, T., Butler, M., Sikkander, S. A., Toida, T., and Linhardt, R. J. (2002) Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. *Carbohydr. Res. 337* (21−23), 2239−43.

(31) Mousa, S. A., Linhardt, R., Francis, J. L., and Amirkhosravi, A. (2006) Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. *Thromb. Haemostasis 96* (6), 816−21.

(32) Yu, L., Garg, H. G., Li, B., Linhardt, R. J., and Hales, C. A. (2010) Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats. *Curr. Cancer Drug Targets 10* (2), 229−241.

(33) O'Reilly, E. M., Roach, J., Miller, P., Yu, K. H., Tjan, C., Rosano, M., Krause, S., Avery, W., Wolf, J., Flaherty, K., Nix, D., and Ryan, D. P. (2017) Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. *Oncologist 22* (12), 1429−e139.

(34) Jones, K. L., McHugh, G. A., Glickstein, L. J., and Steere, A. C. (2009) Analysis of *Borrelia burgdorferi* genotypes in patients with Lyme arthritis: High frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. *Arthritis Rheum. 60* (7), 2174−82.

(35) Fischer, J. R., Parveen, N., Magoun, L., and Leong, J. M. (2003) Decorin-binding proteins A and B confer distinct mammalian cell

type-specific attachment by *Borrelia burgdorferi*, the Lyme disease spirochete. *Proc. Natl. Acad. Sci. U. S. A. 100* (12), 7307−12.

(36) Sadziene, A., Wilske, B., Ferdows, M. S., and Barbour, A. G. (1993) The cryptic *ospC* gene of *Borrelia burgdorferi* B31 is located on a circular plasmid. *Infect. Immun. 61* (5), 2192−5.

(37) Gilmore, R. D., Jr., Howison, R. R., Dietrich, G., Patton, T. G., Clifton, D. R., and Carroll, J. A. (2010) The *bba64* gene of *Borrelia burgdorferi*, the Lyme disease agent, is critical for mammalian infection via tick bite transmission. *Proc. Natl. Acad. Sci. U. S. A. 107* (16), 7515−20.

(38) Hojgaard, A., Eisen, R. J., and Piesman, J. (2008) Transmission dynamics of *Borrelia burgdorferi* s.s. during the key third day of feeding by nymphal Ixodes scapularis (Acari: Ixodidae). *J. Med. Entomol. 45* (4), 732−6.

(39) Stewart, P. E., Wang, X., Bueschel, D. M., Clifton, D. R., Grimm, D., Tilly, K., Carroll, J. A., Weis, J. J., and Rosa, P. A. (2006) Delineating the requirement for the *Borrelia burgdorferi* virulence factor OspC in the mammalian host. *Infection and immunity 74* (6), 3547−53.

(40) Hart, T., Nguyen, N. T. T., Nowak, N. A., Zhang, F., Linhardt, R. J., Diuk-Wasser, M., Ram, S., Kraiczy, P., and Lin, Y. P. (2018) Polymorphic factor H-binding activity of CspA protects Lyme borreliae from the host complement in feeding ticks to facilitate tick-to-host transmission. *PLoS Pathog. 14* (5), e1007106.

(41) Kasumba, I. N., Bestor, A., Tilly, K., and Rosa, P. A. (2016) Virulence of the Lyme disease spirochete before and after the tick bloodmeal: a quantitative assessment. *Parasites Vectors 9*, 129.

(42) Aranjuez, G. F., Kuhn, H. W., Adams, P. P., and Jewett, M. W. (2019) *Borrelia burgdorferi bbk13* Is Critical for Spirochete Population Expansion in the Skin during Early Infection. *Infect. Immun. 87* (5), e00887-18.

(43) Caine, J. A., Lin, Y. P., Kessler, J. R., Sato, H., Leong, J. M., and Coburn, J. (2017) *Borrelia burgdorferi* outer surface protein C (OspC) binds complement component C4b and confers bloodstream survival. *Cell. Microbiol. 19*, e12786.

(44) Parveen, N., Caimano, M., Radolf, J. D., and Leong, J. M. (2003) Adaptation of the Lyme disease spirochaete to the mammalian host environment results in enhanced glycosaminoglycan and host cell binding. *Mol. Microbiol. 47* (5), 1433−44.

(45) Fischer, J. R., LeBlanc, K. T., and Leong, J. M. (2006) Fibronectin binding protein BBK32 of the Lyme disease spirochete promotes bacterial attachment to glycosaminoglycans. *Infection and immunity 74* (1), 435−41.

(46) Benoit, V. M., Fischer, J. R., Lin, Y. P., Parveen, N., and Leong, J. M. (2011) Allelic variation of the Lyme disease spirochete adhesin DbpA influences spirochetal binding to decorin, dermatan sulfate, and mammalian cells. *Infect. Immun. 79* (9), 3501−9.

(47) Lin, Y. P., Chen, Q., Ritchie, J. A., Dufour, N. P., Fischer, J. R., Coburn, J., and Leong, J. M. (2015) Glycosaminoglycan binding by Borrelia burgdorferi adhesin BBK32 specifically and uniquely promotes joint colonization. *Cell. Microbiol. 17* (6), 860−75.

(48) Lee, W. Y., Moriarty, T. J., Wong, C. H., Zhou, H., Strieter, R. M., van Rooijen, N., Chaconas, G., and Kubes, P. (2010) An intravascular immune response to *Borrelia burgdorferi* involves Kupffer cells and iNKT cells. *Nat. Immunol. 11* (4), 295−302.

(49) Moriarty, T. J., Shi, M., Lin, Y. P., Ebady, R., Zhou, H., Odisho, T., Hardy, P. O., Salman-Dilgimen, A., Wu, J., Weening, E. H., Skare, J. T., Kubes, P., Leong, J., and Chaconas, G. (2012) Vascular binding of a pathogen under shear force through mechanistically distinct sequential interactions with host macromolecules. *Mol. Microbiol. 86* (5), 1116−31.

(50) Ebady, R., Niddam, A. F., Boczula, A. E., Kim, Y. R., Gupta, N., Tang, T. T., Odisho, T., Zhi, H., Simmons, C. A., Skare, J. T., and Moriarty, T. J. (2016) Biomechanics of *Borrelia burgdorferi* Vascular Interactions. *Cell Rep. 16* (10), 2593−604.

(51) Lin, Y. P., Bhowmick, R., Coburn, J., and Leong, J. M. (2015) Host cell heparan sulfate glycosaminoglycans are ligands for OspF-related proteins of the Lyme disease spirochete. *Cell. Microbiol. 17* (10), 1464−76.

(52) Fortune, D. E., Lin, Y. P., Deka, R. K., Groshong, A. M., Moore, B. P., Hagman, K. E., Leong, J. M., Tomchick, D. R., and Blevins, J. S. (2014) Identification of Lysine Residues in the Borrelia burgdorferi DbpA Adhesin Required for Murine Infection. *Infect. Immun. 82*, 3186.

(53) Lin, Y. P., Benoit, V., Yang, X., Martinez-Herranz, R., Pal, U., and Leong, J. M. (2014) Strain-specific variation of the decorin-binding adhesin DbpA influences the tissue tropism of the lyme disease spirochete. *PLoS Pathog. 10* (7), e1004238.

(54) Guo, B. P., Brown, E. L., Dorward, D. W., Rosenberg, L. C., and Hook, M. (1998) Decorin-binding adhesins from *Borrelia burgdorferi*. *Mol. Microbiol. 30* (4), 711−23.

(55) Parveen, N., and Leong, J. M. (2000) Identification of a candidate glycosaminoglycan-binding adhesin of the Lyme disease spirochete *Borrelia burgdorferi*. *Mol. Microbiol. 35* (5), 1220−34.

(56) Yang, X., Lin, Y. P., Heselpoth, R. D., Buyuktanir, O., Qin, J., Kung, F., Nelson, D. C., Leong, J. M., and Pal, U. (2016) Middle region of the *Borrelia burgdorferi* surface-located protein 1 (Lmp1) interacts with host chondroitin-6-sulfate and independently facilitates infection. *Cell. Microbiol. 18* (1), 97−110.

(57) Bolz, D. D., Sundsbak, R. S., Ma, Y., Akira, S., Kirschning, C. J., Zachary, J. F., Weis, J. H., and Weis, J. J. (2004) MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. *J. Immunol. 173* (3), 2003−10.

(58) Liu, N., Montgomery, R. R., Barthold, S. W., and Bockenstedt, L. K. (2004) Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in *Borrelia burgdorferi*-infected mice. *Infection and immunity 72* (6), 3195−203.

(59) Shin, O. S., Isberg, R. R., Akira, S., Uematsu, S., Behera, A. K., and Hu, L. T. (2008) Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of *Borrelia burgdorferi* and cytokine induction. *Infection and immunity 76* (6), 2341−51.

(60) Lawrenz, M. B., Wooten, R. M., Zachary, J. F., Drouin, S. M., Weis, J. J., Wetsel, R. A., and Norris, S. J. (2003) Effect of complement component C3 deficiency on experimental Lyme borreliosis in mice. *Infection and immunity 71* (8), 4432−40.

(61) Woodman, M. E., Cooley, A. E., Miller, J. C., Lazarus, J. J., Tucker, K., Bykowski, T., Botto, M., Hellwage, J., Wooten, R. M., and Stevenson, B. (2007) *Borrelia burgdorferi* binding of host complement regulator factor H is not required for efficient mammalian infection. *Infection and immunity 75* (6), 3131−9.

(62) Wang, X., Ma, Y., Weis, J. H., Zachary, J. F., Kirschning, C. J., and Weis, J. J. (2005) Relative contributions of innate and acquired host responses to bacterial control and arthritis development in Lyme disease. *Infection and immunity 73* (1), 657−60.

(63) Schaible, U. E., Kramer, M. D., Museteanu, C., Zimmer, G., Mossmann, H., and Simon, M. M. (1989) The severe combined immunodeficiency (scid) mouse. A laboratory model for the analysis of Lyme arthritis and carditis. *J. Exp. Med. 170* (4), 1427−32.

(64) McKisic, M. D., and Barthold, S. W. (2000) T-cell-independent responses to *Borrelia burgdorferi* are critical for protective immunity and resolution of lyme disease. *Infection and immunity 68* (9), 5190−7.

(65) Barthold, S. W., Sidman, C. L., and Smith, A. L. (1992) Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. *Am. J. Trop. Med. Hyg. 47* (5), 605−13.

(66) Barthold, S. W., and Bockenstedt, L. K. (1993) Passive immunizing activity of sera from mice infected with *Borrelia burgdorferi*. *Infect. Immun. 61* (11), 4696−702.

(67) Fikrig, E., Bockenstedt, L. K., Barthold, S. W., Chen, M., Tao, H., Ali-Salaam, P., Telford, S. R., and Flavell, R. A. (1994) Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis. *J. Infect. Dis. 169* (3), 568−74.

(68) Nadelman, R. B., Nowakowski, J., Fish, D., Falco, R. C., Freeman, K., McKenna, D., Welch, P., Marcus, R., Aguero-Rosenfeld, M. E., Dennis, D. T., and Wormser, G. P. (2001) Tick Bite Study, G., Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an *Ixodes scapularis* tick bite. *N. Engl. J. Med. 345* (2), 79−84.

https://dx.doi.org/10.1021/acsinfecdis.9b00425
ACS Infect. Dis. 2020, 6, 503−514

(69) Wang, Y., Kern, A., Boatright, N. K., Schiller, Z. A., Sadowski, A., Ejemel, M., Souders, C. A., Reimann, K. A., Hu, L., Thomas, W. D., Jr., and Klempner, M. S. (2016) Pre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes. *J. Infect. Dis. 214* (2), 205−11.

(70) Neves, A. R., Correia-da-Silva, M., Sousa, E., and Pinto, M. (2016) Strategies to Overcome Heparins' Low Oral Bioavailability. *Pharmaceuticals 9* (3), 37.

(71) Khatun, Z., Nurunnabi, Cho, K. J., Byun, Y., Bae, Y. H., and Lee, Y. K. (2014) Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. *J. Controlled Release 177*, 64−73.

(72) Alam, F., Al-Hilal, T. A., Chung, S. W., Seo, D., Mahmud, F., Kim, H. S., Kim, S. Y., and Byun, Y. (2014) Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. *Biomaterials 35* (24), 6543−52.

(73) Khatun, Z., Nurunnabi, M., Reeck, G. R., Cho, K. J., and Lee, Y. K. (2013) Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. *J. Controlled Release 170* (1), 74−82.

(74) Berkowitz, S. D., Marder, V. J., Kosutic, G., and Baughman, R. A. (2003) Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. *J. Thromb. Haemostasis 1* (9), 1914−9.

(75) Kurtenbach, K., Dizij, A., Voet, P., Hauser, P., and Simon, M. M. (1997) Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. *Vaccine 15* (15), 1670−4.

(76) Ramana, Y. V., Pandey, A. K., and Singh, S. (1992) Dimethoate toxicity to gestational embryonic ovary of a live bearing fish, Lebistes reticulatus. *Bull. Environ. Contam. Toxicol. 48* (6), 907−13.

(77) Bhattacharya, D., Bensaci, M., Luker, K. E., Luker, G., Wisdom, S., Telford, S. R., and Hu, L. T. (2011) Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease. *Vaccine 29* (44), 7818−25.

(78) Levin, J. D., Johnson, A. W., and Demple, B. (1988) Homogeneous Escherichia coli endonuclease IV. Characterization of an enzyme that recognizes oxidative damage in DNA. *J. Biol. Chem. 263* (17), 8066−8071.

(79) Marcinkiewicz, A. L., Lieknina, I., Kotelovica, S., Yang, X., Kraiczy, P., Pal, U., Lin, Y. P., and Tars, K. (2018) Eliminating Factor H-Binding Activity of *Borrelia burgdorferi* CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine. *Front. Immunol. 9*, 181.

(80) Linhardt, R. J., Rice, K. G., Kim, Y. S., Lohse, D. L., Wang, H. M., and Loganathan, D. (1988) Mapping and quantification of the major oligosaccharide components of heparin. *Biochem. J. 254* (3), 781−7.

(81) Li, L., Zhang, F., Zaia, J., and Linhardt, R. J. (2012) Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. *Anal. Chem. 84* (20), 8822−9.

(82) Li, G., Steppich, J., Wang, Z., Sun, Y., Xue, C., Linhardt, R. J., and Li, L. (2014) Bottom-up low molecular weight heparin analysis using liquid chromatography-Fourier transform mass spectrometry for extensive characterization. *Anal. Chem. 86* (13), 6626−32.

(83) Marcinkiewicz, A. L., Dupuis, A. P., 2nd, Zamba-Campero, M., Nowak, N., Kraiczy, P., Ram, S., Kramer, L. D., and Lin, Y. P. (2019) Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts. *Cell. Microbiol. 21* (2), e12998.

(84) Heroldova, M., Nemec, M., and Hubalek, Z. (1998) Growth parameters of *Borrelia burgdorferi* sensu stricto at various temperatures. *Zentralbl. Bakteriol. 288* (4), 451−5.

(85) Purser, J. E., and Norris, S. J. (2000) Correlation between plasmid content and infectivity in *Borrelia burgdorferi*. *Proc. Natl. Acad. Sci. U. S. A. 97* (25), 13865−70.

(86) Blevins, J. S., Hagman, K. E., and Norgard, M. V. (2008) Assessment of decorin-binding protein A to the infectivity of *Borrelia burgdorferi* in the murine models of needle and tick infection. *BMC Microbiol. 8*, 82.

(87) Bunikis, I., Kutschan-Bunikis, S., Bonde, M., and Bergstrom, S. (2011) Multiplex PCR as a tool for validating plasmid content of *Borrelia burgdorferi*. *J. Microbiol. Methods 86* (2), 243−7.

(88) Hodzic, E., Feng, S., Freet, K. J., and Barthold, S. W. (2003) *Borrelia burgdorferi* population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. *Infection and immunity 71* (9), 5042−55.

(89) Hart, T., Yang, X., Pal, U., and Lin, Y. P. (2018) Identification of Lyme borreliae proteins promoting vertebrate host blood-specific spirochete survival in *Ixodes scapularis* nymphs using artificial feeding chambers. *Ticks and tick-borne diseases 9*, 1057.